
Claudio Passino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2741260/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of controlled breathing, mental activity and mental stress with or without verbalization on heart rate variability. Journal of the American College of Cardiology, 2000, 35, 1462-1469.	2.8	406
2	Predictive value of elevated neutrophil–lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clinica Chimica Acta, 2008, 395, 27-31.	1.1	306
3	Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H17-H29.	3.2	231
4	Human Pathophysiological Adaptations to the Space Environment. Frontiers in Physiology, 2017, 8, 547.	2.8	213
5	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	1.7	183
6	Human Atherosclerotic Plaques Contain Gamma-Glutamyl Transpeptidase Enzyme Activity. Circulation, 2004, 109, 1440-1440.	1.6	172
7	Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1430-1443.	2.8	172
8	Aerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 47, 1835-1839.	2.8	166
9	Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H12-H20.	3.2	165
10	Low-Frequency Spontaneous Fluctuations of R-R Interval and Blood Pressure in Conscious Humans: A Baroreceptor or Central Phenomenon?. Clinical Science, 1994, 87, 649-654.	4.3	157
11	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
12	Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. European Heart Journal, 2001, 22, 1802-1807.	2.2	139
13	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
14	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	3.9	135
15	Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy. Circulation: Cardiovascular Imaging, 2013, 6, 790-799.	2.6	132
16	Combined Increased Chemosensitivity to Hypoxia and Hypercapnia as a Prognosticator in Heart Failure. Journal of the American College of Cardiology, 2009, 53, 1975-1980.	2.8	131
17	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	4.1	127
18	sST2 Predicts Outcome in ChronicÂHeartÂFailure Beyond NTâ^'proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126

#	Article	IF	CITATIONS
19	Demonstrable Cardiac Reinnervation After Human Heart Transplantation by Carotid Baroreflex Modulation of RR Interval. Circulation, 1995, 92, 2895-2903.	1.6	126
20	Impact of exerciseâ€based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data metaâ€analysis of randomised trials. European Journal of Heart Failure, 2018, 20, 1735-1743.	7.1	125
21	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	2.2	121
22	Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review. Clinical Chemistry, 2007, 53, 813-822.	3.2	118
23	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
24	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 637-642.	2.8	107
25	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	4.1	104
26	Origin of Respiratory Sinus Arrhythmia in Conscious Humans. Circulation, 1997, 95, 1813-1821.	1.6	103
27	Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne–Stokes respiration and arrhythmias. Clinical Science, 2008, 114, 489-497.	4.3	98
28	Cardiovascular autonomic modulation and activity of carotid baroreceptors at altitude. Clinical Science, 1998, 95, 565-573.	4.3	97
29	Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clinical Chemistry and Laboratory Medicine, 2004, 42, 627-36.	2.3	93
30	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension, 2016, 67, 606-612.	2.7	90
31	Limitations of Current Echocardiographic Nomograms for Left Ventricular, Valvular, and Arterial Dimensions in Children: A Critical Review. Journal of the American Society of Echocardiography, 2012, 25, 142-152.	2.8	87
32	C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. European Journal of Heart Failure, 2005, 7, 1145-1148.	7.1	86
33	β-Lipoprotein- and LDL-associated serum γ-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis, 2006, 186, 80-85.	0.8	85
34	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. Journal of the American College of Cardiology, 2016, 68, 1420-1431.	2.8	85
35	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€ŧerm comparison. European Journal of Heart Failure, 2018, 20, 700-710.	7.1	84
36	The significance of serum γ-glutamyltransferase in cardiovascular diseases. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1085-91.	2.3	80

#	Article	IF	CITATIONS
37	The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. Clinica Chimica Acta, 2015, 438, 376-381.	1.1	80
38	Old and new biomarkers of heart failure. European Journal of Heart Failure, 2009, 11, 331-335.	7.1	79
39	Synchronous and baroceptor-sensitive oscillations in skin microcirculation: evidence for central autonomic control. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1867-H1878.	3.2	75
40	Influence of Type of Surgery on the Occurrence of Parasympathetic Reinnervation After Cardiac Transplantation. Circulation, 1998, 97, 1368-1374.	1.6	75
41	Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clinica Chimica Acta, 2015, 443, 17-24.	1.1	75
42	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. European Heart Journal, 2008, 29, 2367-2372.	2.2	73
43	Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure. Clinical Chemistry, 2007, 53, 1289-1297.	3.2	71
44	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	2.8	71
45	Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP. Clinical Chemistry, 2005, 51, 445-447.	3.2	70
46	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	1.1	70
47	Respiratory and cardiovascular adaptations to progressive hypoxia. European Heart Journal, 2001, 22, 879-886.	2.2	68
48	Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clinical Chemistry and Laboratory Medicine, 2004, 42, 37-44.	2.3	67
49	Respiratory and Cerebrovascular Responses to Hypoxia and Hypercapnia in Familial Dysautonomia. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 141-149.	5.6	65
50	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	7.1	64
51	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
52	Acute and persistent effects of a 46-kilometre wilderness trail run at altitude: cardiovascular autonomic modulation and baroreflexes. Cardiovascular Research, 1997, 34, 273-280.	3.8	63
53	Risk factors and prognostic value of daytime Cheyne–Stokes respiration in chronic heart failure patients. International Journal of Cardiology, 2009, 137, 47-53.	1.7	63
54	The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1634-1651.	2.3	63

#	Article	IF	CITATIONS
55	Breathing patterns and cardiovascular autonomic modulation during hypoxia induced by simulated altitude. Journal of Hypertension, 2001, 19, 947-958.	0.5	62
56	Effects of physical training on cardiovascular control after heart transplantation. International Journal of Cardiology, 2007, 118, 356-362.	1.7	62
57	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013441.	3.7	62
58	Prognostic Value of Plasma Renin Activity in Heart Failure. American Journal of Cardiology, 2011, 108, 246-251.	1.6	61
59	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	1.5	61
60	Hypoxic Ventilatory Responses and Gas Exchange in Patients with Parkinson's Disease. Respiration, 1998, 65, 28-33.	2.6	60
61	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	3.9	60
62	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	1.7	60
63	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology, 2019, 296, 91-97.	1.7	60
64	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	7.1	60
65	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology, 2020, 27, 1806-1815.	1.8	60
66	Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clinical Chemistry and Laboratory Medicine, 2006, 44, 366-78.	2.3	57
67	Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. European Journal of Preventive Cardiology, 2012, 19, 428-435.	1.8	56
68	Silent myocardial damage in cocaine addicts. Heart, 2011, 97, 2056-2062.	2.9	55
69	Serum Gamma-Glutamyltransferase as a Risk Factor of Ischemic Stroke Might Be Independent of Alcohol Consumption. Stroke, 2002, 33, 1163-1164.	2.0	54
70	Prognostic Value of Combined Measurement of Brain Natriuretic Peptide and Triiodothyronine in Heart Failure. Journal of Cardiac Failure, 2009, 15, 35-40.	1.7	53
71	Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. International Journal of Cardiology, 2009, 136, 80-85.	1.7	53
72	Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. Pharmacological Research, 2020, 155, 104694.	7.1	52

#	Article	IF	CITATIONS
73	Effect of Acetazolamide on Chemosensitivity, Cheyne-Stokes Respiration, and Response to Effort in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 1675-1680.	1.6	51
74	Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2012, 157, 43-47.	1.7	51
75	Prognostic Significance of Central Apneas Throughout a 24-Hour Period in PatientsÂWith Heart Failure. Journal of the American College of Cardiology, 2017, 70, 1351-1364.	2.8	51
76	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 643-648.	2.8	49
77	Ventricular repolarization is prolonged in nondipper hypertensive patients. Journal of Hypertension, 2003, 21, 445-451.	0.5	48
78	Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Advances in Clinical Chemistry, 2019, 93, 239-262.	3.7	46
79	Accuracy of bâ€ <scp>GGT</scp> fraction for the diagnosis of nonâ€alcoholic fatty liver disease. Liver International, 2012, 32, 629-634.	3.9	45
80	Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. American Journal of Clinical Nutrition, 2012, 96, 302-308.	4.7	44
81	Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. Journal of Internal Medicine, 2015, 277, 605-614.	6.0	44
82	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Failure Reviews, 2021, 26, 881-890.	3.9	43
83	Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 79-90.	2.3	42
84	Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. European Journal of Heart Failure, 2006, 8, 46-53.	7.1	41
85	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	1.7	41
86	Hyperthyroidism is associated with lengthening of ventricular repolarization. Clinical Endocrinology, 2001, 55, 27-32.	2.4	40
87	Cardiac production of C-type natriuretic peptide in heart failure. Journal of Cardiovascular Medicine, 2006, 7, 397-399.	1.5	40
88	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. International Journal of Cardiology, 2018, 267, 188-192.	1.7	40
89	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	2.6	40
90	CMR-Verified Interstitial Myocardial Fibrosis as a Marker of Subclinical Cardiac Involvement in LMNA Mutation Carriers. JACC: Cardiovascular Imaging, 2013, 6, 124-126.	5.3	38

#	Article	IF	CITATIONS
91	Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide. Clinical Chemistry, 2005, 51, 1274-1276.	3.2	37
92	Gamma-glutamyltransferase as a cardiovascular risk factor. European Heart Journal, 2006, 27, 2145-2146.	2.2	37
93	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 250, 195-200.	1.7	37
94	Natriuretic Peptides (NPs): Automated Electrochemiluminescent Immunoassay for N-Terminal pro-BNP Compared with IRMAs for ANP and BNP in Heart Failure Patients and Healthy Individuals. Clinical Chemistry, 2003, 49, 1552-1554.	3.2	36
95	Cheyne–Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea. New England Journal of Medicine, 2016, 375, 1004-1006.	27.0	36
96	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	1.7	36
97	Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin I. Clinical Chemistry and Laboratory Medicine, 2018, 56, 492-501.	2.3	36
98	Clinical relevance of biological variation of cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2021, 59, 641-652.	2.3	36
99	Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clinica Chimica Acta, 2013, 417, 19-25.	1.1	35
100	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
101	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e020358.	3.7	34
102	Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regulatory Peptides, 2011, 166, 15-20.	1.9	33
103	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	2.2	33
104	Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 217-230.	7.1	33
105	Ventilation, Autonomic Function, Sleep and Erythropoietin. Advances in Experimental Medicine and Biology, 2003, , 161-175.	1.6	32
106	Cardiovascular risk factors and $\hat{1}^3$ -glutamyltransferase fractions in healthy individuals. Clinical Chemistry and Laboratory Medicine, 2010, 48, 713-717.	2.3	32
107	State of the art of immunoassay methods for B-type natriuretic peptides: An update. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 56-69.	6.1	32
108	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	1.8	32

#	Article	IF	CITATIONS
109	Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I. Clinical Chemistry and Laboratory Medicine, 2018, 56, e229-e231.	2.3	32
110	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	1.7	32
111	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. World Journal of Cardiology, 2015, 7, 621.	1.5	31
112	Upright Cheyne-Stokes Respiration in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2934-2946.	2.8	31
113	Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy?. European Journal of Applied Physiology, 2007, 99, 511-518.	2.5	30
114	Fractions of plasma gamma-glutamyltransferase in healthy individuals: Reference values. Clinica Chimica Acta, 2008, 395, 188-189.	1.1	30
115	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. JACC: Heart Failure, 2017, 5, 735-742.	4.1	30
116	C-type natriuretic peptide and heart failure. Pharmacological Research, 2006, 54, 326-333.	7.1	29
117	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	1.6	29
118	Bâ€ŧype natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. European Journal of Heart Failure, 2019, 21, 1553-1560.	7.1	29
119	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. European Journal of Heart Failure, 2021, 23, 1458-1467.	7.1	29
120	C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 168-172.	2.8	28
121	Circulating Forms of the B-Type Natriuretic Peptide Prohormone. Advances in Clinical Chemistry, 2012, 58, 31-44.	3.7	28
122	Systematic differences between BNP immunoassays: Comparison of methods using standard protocols and quality control materials. Clinica Chimica Acta, 2013, 424, 287-291.	1.1	28
123	Prognostic role of βâ€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	7.1	28
124	Contribution of the Lung to the Genesis of Cheyneâ€Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. Journal of the American Heart Association, 2019, 8, e012419.	3.7	28
125	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	1.8	28
126	Cardiac troponins as biomarkers for cardiac disease. Biomarkers in Medicine, 2019, 13, 325-330.	1.4	28

#	Article	IF	CITATIONS
127	Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial. European Journal of Heart Failure, 2021, 23, 312-320.	7.1	28
128	The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery. Clinical Chemistry and Laboratory Medicine, 2012, 50, 2009-2017.	2.3	27
129	Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. International Journal of Cardiology, 2013, 167, 711-715.	1.7	27
130	Role of Stress Echocardiography in Operated Fallot: Feasibility and Detection of Right Ventricular Response. Journal of the American Society of Echocardiography, 2014, 27, 1319-1328.	2.8	27
131	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. International Journal of Cardiology, 2018, 271, 324-330.	1.7	27
132	Influence of Gender on Circulating Cardiac Natriuretic Hormones in Patients with Heart Failure. Clinical Chemistry and Laboratory Medicine, 2003, 41, 686-92.	2.3	26
133	Abnormal ventricular repolarization in hypertensive patients: role of sympatho-vagal imbalance and left ventricular hypertrophy. International Journal of Cardiology, 2004, 97, 57-62.	1.7	26
134	Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 641-5.	2.3	26
135	Amino-Terminal Fragment of Pro-Brain Natriuretic Hormone Identifies Functional Impairment and Right Ventricular Overload in Operated Tetralogy of Fallot Patients. Pediatric Cardiology, 2007, 28, 339-345.	1.3	26
136	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€ŧerminal proâ€Bâ€ŧype natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	7.1	26
137	Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. International Journal of Cardiology, 2005, 104, 39-45.	1.7	25
138	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	1.7	25
139	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 125.	2.4	25
140	Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives. Journal of Hypertension, 2001, 19, 213-222.	0.5	24
141	Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1178-85.	2.3	24
142	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1515-23.	2.3	24
143	b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. Atherosclerosis, 2014, 237, 307-313.	0.8	24
144	Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. International Journal of Cardiology, 2016, 202, 200-206.	1.7	24

#	Article	IF	CITATIONS
145	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	1.7	24
146	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	7.1	24
147	A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449.	3.4	24
148	Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. International Journal of Cardiovascular Imaging, 2014, 30, 1105-1115.	1.5	23
149	Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival. Endocrine, 2017, 58, 574-581.	2.3	23
150	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). Journal of Cardiac Failure, 2019, 25, 654-665.	1.7	23
151	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	3.1	23
152	Influence of Scal and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure. Clinical Chemistry, 2007, 53, 1886-1890.	3.2	22
153	Clinical relevance of time course of BNP levels in neonates with congenital heart diseases. Clinica Chimica Acta, 2011, 412, 2300-2304.	1.1	22
154	State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). Clinica Chimica Acta, 2015, 444, 106-112.	1.1	22
155	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clinica Chimica Acta, 2015, 443, 85-93.	1.1	22
156	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	1.7	22
157	Autonomic Regulation of Heart Rate and Peripheral Circulation: Comparison of High Altitude and Sea Level Residents. Clinical Science, 1996, 91, 81-83.	0.0	21
158	Exercise intolerance at high altitude (5050m): Critical power and W′. Respiratory Physiology and Neurobiology, 2011, 177, 333-341.	1.6	21
159	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –. Circulation Journal, 2015, 79, 2608-2615.	1.6	21
160	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. International Journal of Cardiology, 2019, 289, 76-82.	1.7	21
161	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European Journal of Preventive Cardiology, 2020, , 204748732092761.	1.8	21
162	Functional connectome of brainstem nuclei involved in autonomic, limbic, pain and sensory processing in living humans from 7 Tesla resting state fMRI. NeuroImage, 2022, 250, 118925.	4.2	21

#	Article	IF	CITATIONS
163	Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1949-54.	2.3	20
164	Low triiodothyronine and exercise capacity in heart failure. International Journal of Cardiology, 2012, 154, 153-157.	1.7	20
165	New issues on measurement of B-type natriuretic peptides. Clinical Chemistry and Laboratory Medicine, 2017, 56, 32-39.	2.3	20
166	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	3.3	20
167	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	4.1	20
168	Functional connectome of arousal and motor brainstem nuclei in living humans by 7 Tesla resting-state fMRI. Neurolmage, 2022, 249, 118865.	4.2	20
169	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	1.7	19
170	Shortâ€ŧerm prognostic implications of serum and urine neutrophil gelatinaseâ€associated lipocalin in acute heart failure: findings from the AKINESIS study. European Journal of Heart Failure, 2020, 22, 251-263.	7.1	19
171	High-sensitivity methods for cardiac troponins: The mission is not over yet. Advances in Clinical Chemistry, 2021, 103, 215-252.	3.7	19
172	Cerebral vasoreactivity in Andeans and headache at sea level. Journal of the Neurological Sciences, 2004, 219, 101-106.	0.6	18
173	Natriuretic Peptide Assays Revisited. Journal of the American College of Cardiology, 2011, 57, 1396-1398.	2.8	18
174	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. European Journal of Heart Failure, 2017, 19, 1701-1709.	7.1	18
175	Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1015-1025.	2.3	18
176	Respiratory Training Late After Fontan Intervention: Impact on Cardiorespiratory Performance. Pediatric Cardiology, 2018, 39, 695-704.	1.3	18
177	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2022, 24, 130-141.	1.2	18
178	Frequency-dependent baroreflex control of blood pressure and heart rate during physical exercise. International Journal of Cardiology, 2006, 107, 171-179.	1.7	17
179	When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease. International Journal of Cardiology, 2011, 148, 161-167.	1.7	17
180	Medium-term effect of sublingual l -glutathione supplementation on flow-mediated dilation in subjects with cardiovascular risk factors. Nutrition, 2017, 38, 41-47.	2.4	17

#	Article	IF	CITATIONS
181	Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic HeartÂFailure. JACC: Heart Failure, 2022, 10, 662-676.	4.1	17
182	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	2.2	16
183	N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. European Journal of Preventive Cardiology, 2016, 23, 366-376.	1.8	16
184	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	3.4	16
185	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1233-1243.	1.8	16
186	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. Diagnostics, 2021, 11, 1378.	2.6	16
187	Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches. Current Pharmaceutical Design, 2016, 22, 4807-4822.	1.9	16
188	Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis. Journal of Cardiac Failure, 2010, 16, 320-326.	1.7	15
189	After the SERVE-HF Trial, Is There Still a Need for Treatment of Central Apnea?. Journal of Cardiac Failure, 2015, 21, 903-905.	1.7	15
190	Vitamin D measurement and effect on outcome in a cohort of patients with heart failure. Endocrine Connections, 2018, 7, 957-964.	1.9	15
191	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. Respiration, 2021, 100, 865-876.	2.6	15
192	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 98, 61-68.	2.2	15
193	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
194	New and emerging biomarkers of heart failure. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 107-128.	6.1	14
195	Cardiac biomarkers and risk assessment in patients undergoing major non-cardiac surgery: time to revise the guidelines?. Clinical Chemistry and Laboratory Medicine, 2014, 52, 959-63.	2.3	14
196	Cardiac Magnetic Resonance Evaluation of Pulmonary Transit Time and Blood Volume in Adult Congenital Heart disease. Journal of Magnetic Resonance Imaging, 2019, 50, 779-786.	3.4	14
197	Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 180-188.	3.0	14
198	Decongestion discriminates risk for oneâ€year mortality in patients with improving renal function in acute heart failure. European Journal of Heart Failure, 2021, 23, 1122-1130.	7.1	14

#	Article	IF	CITATIONS
199	Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 330, 112-119.	1.7	14
200	The combined measurement of high-sensitivity cardiac troponins and natriuretic peptides: a useful tool for clinicians?. Journal of Cardiovascular Medicine, 2020, 21, 953-963.	1.5	14
201	Effective Cardiac Index and Systemic-Pulmonary Collaterals Evaluated by Cardiac Magnetic Resonance Late After Fontan Palliation. American Journal of Cardiology, 2017, 119, 2069-2072.	1.6	13
202	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. European Heart Journal Supplements, 2017, 19, D102-D112.	0.1	13
203	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	3.1	13
204	Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	1.7	13
205	Value in Healthcare and the Role of the Patient Voice. HealthcarePapers, 2019, 18, 28-35.	0.3	13
206	Creatine deficiency and heart failure. Heart Failure Reviews, 2022, 27, 1605-1616.	3.9	13
207	Different Substrates of Non-Sustained Ventricular Tachycardia in Post-infarction Patients With and Without Left Ventricular Dilatation. Journal of Cardiac Failure, 2010, 16, 61-68.	1.7	12
208	Prevalent cardiac phenotype resulting in heart transplantation in a novel LMNA gene duplication. Neuromuscular Disorders, 2010, 20, 512-516.	0.6	12
209	A simple method for measuring baroreflex sensitivity holds prognostic value in heart failure. International Journal of Cardiology, 2013, 169, e9-e11.	1.7	12
210	Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Journal of Cardiovascular Medicine, 2015, 16, 416-422.	1.5	12
211	Evaluation of analytical performance of a chemiluminescence enzyme immunoassay (CLEIA) for cTnl using the automated AIA-CL2400 platform. Clinical Chemistry and Laboratory Medicine, 2018, 56, e174-e176.	2.3	12
212	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. European Journal of Preventive Cardiology, 2018, 25, 889-895.	1.8	12
213	Management of complications of cardiac amyloidosis: 10 questions and answers. European Journal of Preventive Cardiology, 2021, 28, 1000-1005.	1.8	12
214	Serum gammaâ€glutamyl transpeptidase: A prognostic marker in cardiovascular diseases. BioFactors, 2003, 17, 199-205.	5.4	11
215	γ-glutamyltransferase and pathogenesis of cardiovascular diseases. Future Cardiology, 2007, 3, 263-270.	1.2	11
216	Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure. International Journal of Cardiology, 2010, 140, 344-350.	1.7	11

#	Article	IF	CITATIONS
217	Prognostic value of alveolar volume in systolic heart failure: a prospective observational study. BMC Pulmonary Medicine, 2013, 13, 69.	2.0	11
218	Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: new challenges and perspectives. Future Cardiology, 2016, 12, 573-584.	1.2	11
219	The CARPEDIEM Algorithm: A Rule-Based System for Identifying Heart Failure Phenotype with a Precision Public Health Approach. Frontiers in Public Health, 2018, 6, 6.	2.7	11
220	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. European Journal of Preventive Cardiology, 2018, 25, 1419-1430.	1.8	11
221	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. International Journal of Cardiology, 2018, 273, 136-140.	1.7	11
222	Harmonization of two hs-cTnI methods based on recalibration of measured quality control and clinical samples. Clinica Chimica Acta, 2020, 510, 150-156.	1.1	11
223	Piloting a web-based systematic collection and reporting of patient-reported outcome measures and patient-reported experience measures in chronic heart failure. BMJ Open, 2020, 10, e037754.	1.9	11
224	The value of hospital personnel serological screening in an integrated COVID-19 infection prevention and control strategy. Infection Control and Hospital Epidemiology, 2021, 42, 373-374.	1.8	11
225	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 533-541.	1.7	11
226	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 3014-3025.	3.1	11
227	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. International Journal of Cardiology, 2021, 333, 45-50.	1.7	11
228	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	1.8	11
229	Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnl + 3 for the measurement of cardiac troponin I using both patients and quality control plasma samples. Clinica Chimica Acta, 2015, 451, 129-134.	1.1	10
230	Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform. Clinical Chemistry and Laboratory Medicine, 2015, 53, e125-7.	2.3	10
231	A Cross-Correlational Analysis between Electroencephalographic and End-Tidal Carbon Dioxide Signals: Methodological Issues in the Presence of Missing Data and Real Data Results. Sensors, 2016, 16, 1828.	3.8	10
232	Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?. European Journal of Preventive Cardiology, 2017, 24, 1528-1531.	1.8	10
233	Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. Journal of Laboratory and Precision Medicine, 2019, 4, 8-8.	1.1	10
234	Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data. International Journal of Cardiology, 2020, 315, 59-66.	1.7	10

#	Article	IF	CITATIONS
235	Ventilation, autonomic function, sleep and erythropoietin. Chronic mountain sickness of Andean natives. Advances in Experimental Medicine and Biology, 2003, 543, 161-75.	1.6	10
236	Abnormal hyperventilation in patients with hepatic cirrhosis: Role of enhanced chemosensitivity to carbon dioxide. International Journal of Cardiology, 2012, 154, 22-26.	1.7	9
237	Giant Solitary Fibrous Tumor of the Epicardium Causing Reversible Heart Failure. Annals of Thoracic Surgery, 2013, 96, e49-e51.	1.3	9
238	Cocaine assumption and transient myocardial edema in asymptomatic cocaine heavy-users. International Journal of Cardiology, 2014, 173, 614-615.	1.7	9
239	Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 567-572.	1.6	9
240	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. International Journal of Cardiology, 2020, 307, 187-192.	1.7	9
241	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	6.1	9
242	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 252-258.	3.0	9
243	Markers of Arrhythmogenic Risk in Hypertensive Subjects. Current Pharmaceutical Design, 2011, 17, 3062-3073.	1.9	8
244	Influence of preload and afterload on stroke volume response to low-dose dobutamine stress in patients with non-ischemic heart failure: A cardiac MR study. International Journal of Cardiology, 2013, 166, 475-481.	1.7	8
245	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	1.7	8
246	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clinical Chemistry and Laboratory Medicine, 2021, 59, 513-521.	2.3	8
247	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clinical Chemistry and Laboratory Medicine, 2021, 59, 51-57.	2.3	8
248	Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse. British Journal of Haematology, 2000, 109, 895-896.	2.5	7
249	B-type natriuretic peptide secretion following scuba diving. Biomarkers in Medicine, 2011, 5, 205-209.	1.4	7
250	Forced expiratory volume in one second: Prognostic value in systolic heart failure. International Journal of Cardiology, 2013, 168, 1573-1574.	1.7	7
251	Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. Clinica Chimica Acta, 2013, 416, 48-49.	1.1	7
252	Evaluation and Comparison with Other High-Sensitivity Methods of Analytical Performance and Measured Values of a New Laboratory Test for Cardiac Troponin I Assay. journal of applied laboratory medicine, The, 2021, 6, 1237-1250.	1.3	7

#	Article	IF	CITATIONS
253	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. American Journal of Cardiology, 2021, 147, 70-79.	1.6	7
254	Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure. PLoS ONE, 2016, 11, e0153510.	2.5	7
255	Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, e024103.	3.7	7
256	Speckle tracking echocardiography in heart failure development and progression in patients with apneas. Heart Failure Reviews, 2022, 27, 1869-1881.	3.9	7
257	Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas. European Journal of Applied Physiology, 2000, 83, 481-486.	2.5	6
258	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. European Journal of Preventive Cardiology, 2017, 24, 1718-1724.	1.8	6
259	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. International Journal of Cardiology, 2018, 267, 141-142.	1.7	6
260	The paradox of low Bâ€ŧype natriuretic peptide levels in obesity revisited: does sex matter?. European Journal of Heart Failure, 2018, 20, 1215-1216.	7.1	6
261	Impact of right atrium dimension on adverse outcome after pulmonary valve replacement in repaired Tetralogy of Fallot patients. International Journal of Cardiovascular Imaging, 2020, 36, 1973-1982.	1.5	6
262	Ld-EEG Effective Brain Connectivity in Patients With Cheyne-Stokes Respiration. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2020, 28, 1216-1225.	4.9	6
263	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. International Journal of Cardiology, 2021, 336, 98-104.	1.7	6
264	Flow-Diameter Phase Shift. Hypertension, 1995, 26, 20-25.	2.7	6
265	Decongestion, kidney injury and prognosis in patients with acute heart failure. International Journal of Cardiology, 2022, 354, 29-37.	1.7	6
266	The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases. Vascular Disease Prevention, 2006, 3, 205-209.	0.2	5
267	Treating chemoreflex in heart failure: modulation or demolition?. Journal of Physiology, 2014, 592, 1903-1904.	2.9	5
268	No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril. Journal of the American College of Cardiology, 2019, 73, 3037-3038.	2.8	5
269	Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment?. World Journal of Cardiology, 2015, 7, 824.	1.5	5
270	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Failure Reviews, 2022, , .	3.9	5

#	Article	IF	CITATIONS
271	Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. Clinical Chemistry and Laboratory Medicine, 2014, 52, e21-3.	2.3	4
272	Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance. International Journal of Cardiology, 2014, 176, 1396-1398.	1.7	4
273	Targeting Periodic Breathing in Heart Failure Patients, and Treating It—Gently. Journal of Cardiac Failure, 2014, 20, 289-291.	1.7	4
274	Correlational analysis of electroencephalographic and end-tidal carbon dioxide signals during breath-hold exercise. , 2015, 2015, 6102-5.		4
275	Glycosylated haemoglobin is associated with neurohormonal activation and poor outcome in chronic heart failure patients with mild left ventricular systolic dysfunction. Journal of Cardiovascular Medicine, 2015, 16, 423-430.	1.5	4
276	How to take arms against central apneas in heart failure. Expert Review of Cardiovascular Therapy, 2017, 15, 743-755.	1.5	4
277	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	3.0	4
278	Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction. Clinical Research in Cardiology, 2021, 110, 711-724.	3.3	4
279	Effects of central apneas on sympathovagal balance and hemodynamics at night: impact of underlying systolic heart failure. Sleep and Breathing, 2021, 25, 965-977.	1.7	4
280	The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, e203-e204.	1.8	4
281	Early evaluation of myocardial injury by means of high-sensitivity methods for cardiac troponins after strenuous and prolonged exercise. Journal of Sports Medicine and Physical Fitness, 2020, 60, 1297-1305.	0.7	4
282	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. Scientific Reports, 2022, 12, 4691.	3.3	4
283	The authors of the article cited above respond:. Clinical Chemistry, 2007, 53, 1720-1721.	3.2	3
284	Persistence of baroreceptor control of cerebral blood flow velocity at a simulated altitude of 5000 m. Journal of Hypertension, 2007, 25, 1862-1870.	0.5	3
285	Plasma leptin and vascular endothelial growth factor (VEGF) in normal subjects at high altitude (5050 m). Archives of Physiology and Biochemistry, 2013, 119, 219-224.	2.1	3
286	Response to Letters Regarding Article, "Myocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Study― Circulation: Cardiovascular Imaging, 2013, 6, e79.	2.6	3
287	Leiomyosarcoma of the inferior vena cava in a patient with Budd-Chiari syndrome. Revista Portuguesa De Cardiologia, 2014, 33, 807-809.	0.5	3
288	Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform. Clinical Chemistry and Laboratory Medicine, 2019, 57, 911-917.	2.3	3

#	Article	IF	CITATIONS
289	Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure, 2021, 8, 719-724.	3.1	3
290	Natriuretic peptide testing in primary care patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1533-42.	2.3	2
291	Single-Shot Cardiorenal Scintigraphy with ^{99m} Tc-Tetrofosmin: A Dynamic Characterization at Rest and During Adenosine Infusion. Journal of Nuclear Medicine, 2009, 50, 1288-1295.	5.0	2
292	Breathless Heart. Journal of the American College of Cardiology, 2013, 61, 1167-1168.	2.8	2
293	Surgery Casualties. Journal of the American College of Cardiology, 2014, 63, 181-183.	2.8	2
294	Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction. Clinical Chemistry, 2017, 63, 1045-1046.	3.2	2
295	N-terminal fragment of B-type natriuretic peptide predicts coexisting subclinical heart and vessel disease. Journal of Cardiovascular Medicine, 2017, 18, 750-757.	1.5	2
296	Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms?. International Journal of Cardiology, 2018, 254, 248-249.	1.7	2
297	Healthy aging: the INTECMAN project. Aging Clinical and Experimental Research, 2021, 33, 2011-2015.	2.9	2
298	Effects of nasal high flow on sympathovagal balance, sleep, and sleep-related breathing in patients with precapillary pulmonary hypertension. Sleep and Breathing, 2021, 25, 705-717.	1.7	2
299	The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in communityâ€dwelling individuals. European Journal of Heart Failure, 2021, 23, 403-405.	7.1	2
300	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.6	2
301	Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart, 2021, 107, 989-995.	2.9	2
302	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. Journal of Cardiovascular Translational Research, 2022, , 1.	2.4	2
303	Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, 1510-1518.	1.8	2
304	Clinical Applications in Extra-Cardiac Diseases. , 2006, , 133-160.		1
305	Can We Measure How Hot the Plaque Is? Not Yet, But…. Journal of the American College of Cardiology, 2013, 62, 338-339.	2.8	1
306	Renal denervation in resistant arterial hypertension: Effects on neurohormonal activation and cardiac natriuretic peptides. International Journal of Cardiology, 2015, 184, 574-575.	1.7	1

#	Article	IF	CITATIONS
307	The search for efficient diagnostic and prognostic biomarkers of heart failure. Future Cardiology, 2016, 12, 327-337.	1.2	1
308	Exploratory analysis of nonlinear coupling between EEG global field power and end-tidal carbon dioxide in free breathing and breath-hold tasks. , 2016, 2016, 728-731.		1
309	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly <i>?</i> . European Journal of Heart Failure, 2017, 19, 549-551.	7.1	1
310	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. International Journal of Cardiology, 2017, 248, 278-279.	1.7	1
311	Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. International Journal of Cardiology, 2018, 250, 231-232.	1.7	1
312	Heart, kidney and FGF23: Les liaisons dangereuses. International Journal of Cardiology, 2018, 253, 120-121.	1.7	1
313	Heart rate response to exercise and prognosis: Does rhythm matter?. European Journal of Preventive Cardiology, 2018, 25, 1632-1633.	1.8	1
314	Left ventricular ejection fraction and coronary artery disease in the era of precision medicine. European Journal of Preventive Cardiology, 2019, 26, 1271-1272.	1.8	1
315	Breath-hold task induces temporal heterogeneity in electroencephalographic regional field power in healthy subjects. Journal of Applied Physiology, 2021, 130, 298-307.	2.5	1
316	Central apneas, chemoreflex sensitivity, and buspirone in spinal cord injury: a word of caution. Journal of Applied Physiology, 2021, 130, 756-757.	2.5	1
317	Mapping dependencies of BOLD signal change to end-tidal CO2: Linear and nonlinear modeling, and effect of physiological noise correction. Journal of Neuroscience Methods, 2021, 362, 109317.	2.5	1
318	Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H12-H20.	3.2	1
319	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	1.5	1
320	Response to the Letter: Sleep-Disordered Breathing in Precapillary Pulmonary Hypertension: Is the Prevalence So High? Reference Article: Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants and Clinical Consequences by Zheng Z et al Respiration, 2022, 101, 433-435.	2.6	1
321	The clinical diagnosis of heart failure is predicted by neurohormonal and immune derangement. Immuno-Analyse Et Biologie Specialisee, 2003, 18, 207-211.	0.0	0
322	Angiotensin II radioimmunoassay in patients with heart failure: methodological and clinical assessment. Immuno-Analyse Et Biologie Specialisee, 2004, 19, 105-109.	0.0	0
323	Cardiac natriuretic hormones as clinical markers: instructions for use. Future Cardiology, 2006, 2, 619-622.	1.2	0
324	Ventricular Repolarization in Hypertension: Beyond Bazett. American Journal of Hypertension, 2008, 21, 9-9.	2.0	0

#	Article	IF	CITATIONS
325	The Month After. Journal of the American College of Cardiology, 2011, 58, 1967-1969.	2.8	о
326	PLASMA RENIN ACTIVITY AND ANGIOTENSINOGEN M235T POLYMORPHISM ARE DETERMINANTS OF ALDOSTERONE ESCAPE IN PATIENTS WITH SYSTOLIC HEART FAILURE. Journal of the American College of Cardiology, 2011, 57, E260.	2.8	0
327	Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. International Journal of Cardiology, 2017, 236, 348-349.	1.7	Ο
328	To Breathe, or Not to Breathe: That Is the Question. , 2017, , 203-217.		0
329	SYMPATHETIC RENAL DENERVATION AFTER ACUTE MYOCARDIAL INFARCTION BLUNTS ADRENERGIC ACTIVATION AND INCREASED MYOCARDIAL SALVAGE IN PIGS. Journal of the American College of Cardiology, 2018, 71, A175.	2.8	Ο
330	Tireless cardiologists needed for (very) tired patients: The case of heart failure. European Journal of Preventive Cardiology, 2018, 25, 1702-1703.	1.8	0
331	Reply. Journal of the American College of Cardiology, 2020, 76, 2040-2041.	2.8	Ο
332	Analysis of the logistical, economic and minimally invasive cardiac surgical training difficulties in India. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 178-185.	1.0	0
333	Novel Drug Targets for Central Apneas in Heart Failure: On the Road. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 490-491.	5.6	Ο
334	Hide and seek. Ticagrelor and central apneas after acute coronary syndrome. Sleep Medicine, 2021, 86, 125.	1.6	0
335	Abstract 14182: Myocardial Fibrosis and Reverse Remodelling in Nonischaemic Dilated Cardiomyopathy. Circulation, 2015, 132, .	1.6	Ο
336	Breathless Heart: Final Remarks. , 2017, , 285-287.		0
337	Diagnostic Tools: The Easier, the Better. , 2017, , 219-234.		0

338 Targeting and Treating Apneas. , 2017, , 247-270.

0